DBV Technologies ADR Dossier
Qualitative Analysis
Business overview
DBV Technologies S.A. is a late-stage clinical biopharmaceutical company dedicated to developing non-invasive, safe, and effective immunotherapies for food allergies and other immunologic conditions with significant unmet medical needs. The company's core scientific innovation is its proprietary Viaskin epicutaneous patch platform, which delivers microgram amounts of biologically active compounds (such as allergens) to the immune system through intact skin. This process, known as Epicutaneous Immunotherapy (EPIT), aims to re-educate the immune system and desensitize patients to specific allergens. DBV's primary clinical focus is the development of the Viaskin Peanut Patch to treat peanut allergies in pediatric populations, specifically targeting toddlers (ages 1 to 3) and children (ages 4 to 7).
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Building out commercial infrastructure in the United States in anticipation of potential FDA approval, including market access, patient services, brand readiness, field force planning, and launch operations.
Expected impact: Enables rapid commercialization and market penetration of the VIASKIN Peanut Patch upon regulatory approval.
Filing a shelf registration statement to refresh its ATM offering program, allowing for the sale of up to $150 million in American Depositary Shares (ADSs).
Expected impact: Secures flexible capital to fund manufacturing expansion, BLA submissions, and launch preparations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
FLV will exclusively manufacture and supply the Viaskin Peanut Source Material (PSM) to support commercial scale-up.
Terms: Includes terms related to manufacturing, quality control, pricing, and volume commitments over an initial 8-year term.
Sanofi exclusively manufactures and supplies the Viaskin Peanut Active Pharmaceutical Ingredient (API) for DBV.
Terms: Initial 4-year term effective from January 1, 2025, with options to extend.